| Literature DB >> 26793626 |
Saeedeh Shenavandeh1, Maryam Zarei Nezhad2.
Abstract
BACKGROUND: The present study aimed to investigate the Nailfold Capillaroscopy (NC) features of the patients with dermatomyositis (DM) and its correlation with their disease activity indices, physical findings, and laboratory results.Entities:
Keywords: Capillaroscopy; Dermatomyositis; Nails
Year: 2015 PMID: 26793626 PMCID: PMC4715380
Source DB: PubMed Journal: Med J Islam Repub Iran ISSN: 1016-1430
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Presence of different clinical and laboratory findings in patients with dermatomyositis
| Present n(%) | Absence n(%) | |
| Pyrexia | 8(29.7%) | 19(70.3%) |
| Weight loss | 15(55.5%) | 12(45.5%) |
| Fatigue | 20(74.1%) | 7(25.9%) |
| Cutaneous ulceration | 12(45.5%) | 15(55.5%) |
| Erythroderma | 12(45.5%) | 15(55.5%) |
| Panniculitis | 1(3.7%) | 26(96.3%) |
| Erythematous rashes: | ||
| Heliotrope rash | 12(45.5%) | 15(55.5%) |
| Gottron’s papules/sign | 24(88.9%) | 3(11.1%) |
| Periungual capillary changes | 25(92.6%) | 2(7.4%) |
| Alopecia | ||
| Mechanics hands | 12(45.5%) | 15(55.5%) |
| Arthritis | ||
| Arthralgia | 15(55.5%) | 12(45.5%) |
| Dysphagia: | ||
| Abdominal pain | ||
| xRespiratory muscle weakness withoutILD†: | ||
| Active reversible ILD | ||
| Dysphonia: | ||
| Pericarditis | 1(3.7%) | 26(96.3%) |
| Myocarditis | 0 | 27(100%) |
| Arrhythmia: | ||
| Sinus tachycardia | 7(25.9%) | 20(74.1%) |
| Myositis: | ||
| Myalgia | 4(14.8%) | 23(85.2%) |
*e.g. accompanied by erosions, vesiculobullous change or necrosis, †ILD: interstitial lung disease, ‡HRCT: high resolution CT scan, §FVC: Functional vital capacity
Presence of different anomalous morphologies in our patients with dermatomyositis
| Presence, n(%) | Absence, n(%) | |
|
Neoangiogenesis |
20(74%) |
7(26%) |
Association between different scleroderma patterns and clinical or laboratory features
| Features | Scleroderma pattern | ||||
| Early pattern n (%) | Active pattern n (%) | Late pattern n (%) | Non-specific pattern n (%) | p | |
|
Symptoms and | |||||
| Fever | 1(16.7%) | 3(50%) | 1(16.7%) | 1(16.7%) | 0.20 |
| Heliotrope rash | 0 | 6(50%) | 4(33.3%) | 2(16.7%) | 1 |
| Gottron papules | 1(4.3%) | 8(34.8%) | 11(47.8%) | 3(13%) | 1 |
| Gottron's sign | 0 | 8(42.1%) | 10(52.6%) | 1(5.3%) | 0.56 |
| V sign | 1(4.3%) | 2(28.6%) | 3(42.9%) | 1(14.3%) | 0.76 |
| Shawl sign | 0 | 2(66.7%) | 1(33.3%) | 0 | 0.41 |
| Preorbital edema | 1(16.7%) | 2(33.3%) | 2(33.3%) | 1(16.7%) | 0.53 |
| Calcification | 0 | 5(50%) | 4(40%) | 1(10%) | 0.60 |
| Mechanic hand | 1(8.3%) | 4(33.3%) | 6(50%) | 1(8.3%) | 0.60 |
| Facial erythema | 1(16.7%) | 7(46.7%) | 6(40%) | 1(6.7%) | 0.06 |
| Arthritis | 1(25%) | 1(25%) | 1(25%) | 1(25%) | 0.71 |
| Polyarthralgia | 1(16.7%) | 7(46.7%) | 6(40%) | 1(6.7%) | 0.06 |
| ILD* | 0 | 3(33.3%) | 4(44.4%) | 2(22.2%) | 0.41 |
| Dysphasia | 0 | 3(37.5%) | 4(50%) | 1(12.5%) | 1 |
| Muscle weakness | 0 | 9(45%) | 9(45%) | 2(10%) | 0.56 |
| Laboratory findings, % | |||||
| CK† | 25% | 17.9% | 7.1% | 50% | 0.29 |
| ESR‡ | 1(5.5%) | 8(44.5%) | 7(38.9%) | 2(11.1%) | 0.16 |
| CRP§ | 0 | 2(40%) | 2(40%) | 1(20%) | 1 |
| ANA|| | 1(7.7%) | 5(38.5%) | 7(53.8%) | 0 | 0.11 |
| Anti RO antibody | 0 | 0 | 4(100%) | 0 | 0.46 |
| Anti JO1 antibody | 0 | 2(50%) | 2(50%) | 0 | 0.71 |
| Myopathic EMG¶ | 1(5.3%) | 9(47.3%) | 8(42.1%) | 1(5.3%) | 0.015 |
*ILD: Interstitial lung disease, †CK: creatine kinase, ‡ESR: Erythrocyte sedimentation rate. A level of >12 in male and >18 in female was considered abnormal [52]. §CRP: C-Reactive Protein. A level of >5 mg/L was considered as abnormal.
||ANA: Antinuclear antibody, ¶EMG: electromyography
Association between myositis disease activity organ systems and scleroderma pattern in patients with dermatomyositis
|
Myositis disease activity | Scleroderma pattern (Mean± SD*) |
Non-specific pattern | p |
|
Constitutional disease activity |
2.92±2.50 |
4.67±3.05 |
0.30 |
*SD: Standard deviation
Association between nailfoldcapillaroscopy features and myositis disease activity organ systems in our patients with dermatomyositis
| Myositis disease activity organ systems, (Mean±SD*) |
Dilated | Avascular areas | Elongated capillary loops |
Microhem | Distribution | Neoangiogenesis | Giant loop | p |
| Constitutional disease activity | 3±2.5( 0.69) | 2.7±2.2(0.39) | 5±3(0.068) | 2.8±2.3(0.39) | 3±2.6(0.87) | 2.8±2.6(0.40) | 3.5±2.6(0.50) | 3.7±2.3(0.60) |
| Cutaneous disease activity | 3.5±2.2(0.92) | 3.5±2.1(0.95) | 4.4±2.3(0.27) | 3.2±2.1(0.51) | 3.4±2.1(1) | 3.5±2.5(0.84) | 3.6±1.8(0.72) | 4±2.3(0.53) |
| Skeletal disease activity | 2±2.4(0.32) | 1.9±2(0.91) | 3.6±2.9(0.063) | 1.7±2(0.66) | 1.9±2.3(1) | 1.9±12.2(0.86) | 2.5±2.8(0.24) | 3±2.3(0.18) |
| Gastrointestinal disease activity | 1±2.8(0.52) | 1.3±2.2(0.93) | 1.6±3.6(0.82) | 0.9±1.9( 0.22) | 1.5±2.5(0.72) | 1.5±2.5(0,68) | 1.1±2.6(0.65) | 0(0.16) |
| Pulmonary disease activity | 2.1±2.9(0.39) | 1.7±2.8(0.63) | 3.2±3.3(0.27) | 1.6±2.7( 0.38) | 2±2.8(1) | 1.8±2.8(0.64) | 2.4±3(0.48) | 3.2±3.3(0.25) |
| Cardiac disease activity | 1±1.7(0.33) | 0.7±1.6(0.67) | 1.4±2(0.40) | 1±1.6( 0.56) | 0.9±1.7(0.76) | 0.9±1.6(0.92) | 1.1±1.8(0.57) | 1.7±2.1(0.24) |
| Muscular disease activity | 4.1±3.1(0.96) | 4.1±2.8(0.99) | 5.6±3.2(0.21) | 4±3(0.95) | 4.3±3(0.16) | 3.8±3.3(0.48) | 4.7±2.8(0.37) | 5.8±1.6(0.11) |
| Global disease activity |
5.4±2.4(0.64) |
5.1±2.5(0.70) |
6.4±3(0.27) | 5.5±2.3(0.57) | 5.4±2.5(0.47) | 5.2±2.6(0.79) | 5.5±2.6(0.70) | 6.7±1.7(0.13) |
*SD: Standard deviation